Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Multicentre, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy and Pharmacodynamics After the Intravenous Administration of CAL02 in Severe Community-acquired Pneumonia Due to Streptococcus Pneumoniae

NCT02583373 is registered in ClinicalTrials.gov with Combioxin SA as lead sponsor.

NCT NCT02583373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02583373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Multicentre, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy and Pharmacodynamics After the Intravenous Administration of CAL02 in Severe Community-acquired Pneumonia Due to Streptococcus Pneumoniae
Lead sponsor
Combioxin SA
Phase
Phase 1
Overall status
Completed
Start date
March 21, 2016
Completion date
February 20, 2018
Enrollment
19 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal infections, pneumonia